IO Biotech Inc (IOBT)

[axelvento]

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California.

https://www.stocktitan.net/news/IOBT/io-biotech-announces-new-preclinical-data-for-additional-pipeline-oc2de280qehy.html

https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Announces-New-Preclinical-Data-for-Additional-Pipeline-Candidate-Presented-at-the-AACR-IO-Conference/default.aspx